VVOS Stock Overview
A medical technology company, develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Vivos Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.13 |
| 52 Week High | US$48.79 |
| 52 Week Low | US$1.96 |
| Beta | 7.99 |
| 1 Month Change | -19.32% |
| 3 Month Change | -56.97% |
| 1 Year Change | -79.01% |
| 3 Year Change | -98.46% |
| 5 Year Change | n/a |
| Change since IPO | -99.05% |
Recent News & Updates
Recent updates
It's Down 44% But Vivos Therapeutics, Inc. (NASDAQ:VVOS) Could Be Riskier Than It Looks
Apr 25
It's Down 48% But Vivos Therapeutics, Inc. (NASDAQ:VVOS) Could Be Riskier Than It Looks
Feb 02Fewer Investors Than Expected Jumping On Vivos Therapeutics, Inc. (NASDAQ:VVOS)
Apr 18Vivos Therapeutics again delays Q2 2022 results
Aug 23Vivos Therapeutics signs exclusive distribution agreement with GM Instruments for US and Canada
Jun 29Vivos Therapeutics, Inc. (NASDAQ:VVOS) Analysts Are More Bearish Than They Used To Be
May 21Vivos Therapeutics: First Take After The Broad Market Sell-Off
Mar 06Vivos Therapeutics: Reimagining Sleep
Jul 30Vivos Therapeutics prices $24M follow-on offering
May 07Shareholder Returns
| VVOS | US Healthcare | US Market | |
|---|---|---|---|
| 7D | -2.3% | 1.0% | 1.2% |
| 1Y | -79.0% | 6.9% | 27.7% |
Return vs Industry: VVOS underperformed the US Healthcare industry which returned 6.9% over the past year.
Return vs Market: VVOS underperformed the US Market which returned 27.7% over the past year.
Price Volatility
| VVOS volatility | |
|---|---|
| VVOS Average Weekly Movement | 14.8% |
| Healthcare Industry Average Movement | 6.7% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: VVOS's share price has been volatile over the past 3 months.
Volatility Over Time: VVOS's weekly volatility has decreased from 120% to 15% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 119 | R. Huntsman | www.vivos.com |
Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children.
Vivos Therapeutics, Inc. Fundamentals Summary
| VVOS fundamental statistics | |
|---|---|
| Market cap | US$6.56m |
| Earnings (TTM) | -US$15.64m |
| Revenue (TTM) | US$13.36m |
0.5x
P/S Ratio-0.4x
P/E RatioIs VVOS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VVOS income statement (TTM) | |
|---|---|
| Revenue | US$13.36m |
| Cost of Revenue | US$5.49m |
| Gross Profit | US$7.87m |
| Other Expenses | US$23.51m |
| Earnings | -US$15.64m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -5.25 |
| Gross Margin | 58.90% |
| Net Profit Margin | -117.06% |
| Debt/Equity Ratio | 0% |
How did VVOS perform over the long term?
See historical performance and comparison